Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease

Experimental Neurology

Volumn 188, Issue 2, 2004, Pages 268-278

  O'Neill, Kathleen ^a   Chen, Shuhua ^a   Brinton, Roberta Diaz ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

4 hydroxy tamoxifen; Basal forebrain; Cortex; Estrogen; Estrogen receptor; Hippocampus; Neuroprotection; Neurotrophism; SERM; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; AMYLOID BETA PROTEIN[25-35]; ESTRADIOL; ESTROGEN; GLUTAMIC ACID; LACTATE DEHYDROGENASE; NEUROPROTECTIVE AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGING; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENZYME RELEASE; FOREBRAIN; HIPPOCAMPUS; IN VITRO STUDY; MEMORY; NERVE CELL CULTURE; NERVE CELL GROWTH; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

AGING; ALZHEIMER DISEASE; ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGENS; EXCITATORY AMINO ACIDS; GLUTAMIC ACID; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 3042751870     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.01.014     Document Type: Article

References (67)

1. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262:1987;5592-5595
2. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. U. S. A. 90:1993;7915-7922
3. Behl C., Skutella T., Lezoualc'h F., Post A., Widmann M., Newton C.J., Holsboer F. Neuroprotection against oxidative stress by estrogens: structure- activity relationship. Mol. Pharmacol. 51:1997;535-541
4. Biegon A., Brewster M., Degani H., Pop E., Somjen D., Kaye A.M. A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Cancer Res. 56:1996;4328-4331
5. Brinton R.D. 17 β-estradiol induction of filopodial growth in cultured hippocampal neurons within minutes of exposure. Mol. Cell. Neurosci. 4:1993;36-46
6. Brinton R.D. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn. Mem. 8:2001;121-133
7. Brinton R.D. Selective Estrogen Receptor Modulators (SERM) for the brain: recent advances and remaining challenges for developing a neuroserm. Drug Dev. Res., Spec. Issue Drug Dev. Alzheimer's Dis. 56:2002;380-392
8. Brinton R.D., Proffitt P., Tran J., Luu R. Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of cortical neurons via an NMDA receptor- dependent mechanism. Exp. Neurol. 147:1997;211-220
9. Brinton R.D., Tran J., Proffitt P., Montoya M. 17 beta-Estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem. Res. 22:1997;1339-1351
10. Brinton R.D., Chen S., Montoya M., Hsieh D., Minaya J. The estrogen replacement therapy of the women's health Initiative promotes the cellular mechanisms of memory and neuronal survival in neurons vulnerable to Alzheimer's disease. Maturitas. 34:2000;1
11. Bruning P.F. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur. J. Cancer. 1992;1404-1407
12. Catherino W.H., Jordan V.C. A risk-benefit assessment of tamoxifen therapy. Drug Saf. 8:1993;381-397
13. Chae H.S., Bach J.H., Lee M.W., Kim H.S., Kim Y.S., Kim K.Y., Choo K.Y., Choi S.H., Park C.H., Lee S.H., Suh Y.H., Kim S.S., Lee W.B. Estrogen attenuates cell death induced by carboxy-terminal fragment of amyloid precursor protein in PC12 through a receptor-dependent pathway. J. Neurosci. Res. 65:2001;403-407
14. Chen Q., Oji G., Brinton R.D. Effect of select phytoestrogens on plasticity and survival of cultured rat hippocampal neurons. Society for Neuroscience 28th Annual Meeting, Los Angeles, CA. 1998
15. Chen D., Wu C.F., Shi B., Xu Y.M. Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol. Biochem. Behav. 71:2002;269-276
16. Coezy E., Borgna J.L., Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42:1982;317-323
17. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer. 25:1971;270-275
18. Cosman F., Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr. Rev. 20:1999;418-434
19. Diaz Brinton R., Chen S., Montoya M., Hsieh D., Minaya J., Kim J., Chu H.P. The women's health initiative estrogen replacement therapy is neurotrophic and neuroprotective. Neurobiol. Aging. 21:2000;475-496
20. Eppenberger U., Wosikowski K., Kung W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am. J. Clin. Oncol. 14:1991;S5-S14
21. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project p-1 study. J. Natl. Cancer Inst. 90:1998;1371-1388
22. Gerber B., Krause A. New data concerning breast carcinoma. A report on the 34th meeting of the American society of clinical oncology, Los Angeles, Calif., USA, May 16-19, 1998. Gynäkol.-Geburtshilfliche Rundsch. 39:1999;136-139
23. Green P.S., Gordon K., Simpkins J.W. Phenolic a ring requirement for the neuroprotective effects of steroids. J. Steroid Biochem. Mol. Biol. 63:1997;229-235
24. Grill H.J., Pollow K. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients. Am. J. Clin. Oncol. 14:1991;S21-S29
25. Harper M.J., Walpole A.L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. Fertil. 13:1967;101-119
26. Hogervorst E., Yaffe K., Richards M., Huppert F. Hormone replacement therapy for cognitive function in postmenopausal women. (Cochrane Review) The Cochrane Library, Issue 1. 2004
27. Hogervorst E., Yaffe K., Richards M., Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. (Cochrane Review) The Cochrane Library, Issue 1. 2004
28. Hoyt K.R., McLaughlin B.A., Higgins D.S. Jr., Reynolds I.J. Inhibition of glutamate-induced mitochondrial depolarization by tamoxifen in cultured neurons. J. Pharmacol. Exp. Ther. 293:2000;480-486
29. Jordan V.C. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res. Treat. 3:1983;S73-S86
30. Jordan V.C., Koerner S. Tamoxifen (ICI 46, 474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer. 11:1975;205-206
31. Jordan V.C., Collins M.M., Rowsby L., Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75:1977;305-316
32. Katzenellenbogen J.A., O'Malley B.W., Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 10:1996;119-131
33. Kawamura I., Mizota T., Kondo N., Shimomura K., Kohsaka M. Antitumor effects of droloxifene, a new antiestrogen drug, against 7, 12- dimethylbenz(a)anthracene-induced mammary tumors in rats. Jpn. J. Pharmacol. 57:1991;215-224
34. Kimelberg H.K., Feustel P.J., Jin Y., Paquette J., Boulos A., Keller R.W. Jr., Tranmer B.I. Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. NeuroReport. 11:2000;2675-2679
35. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:1997;863-870
36. Lerner L.J., Hilf R., Turkheimer A.R., Michel I., Engel S.L. Effects of hormone antagonists on morphological and biochemical changes induced by hormonal steroids in the immature rat uterus. Endocrinology. 78:1966;111-124
37. Lien E.A., Solheim E., Lea O.A., Lundgren S., Kvinnsland S., Ueland P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49:1989;2175-2183
38. Lien E.A., Solheim E., Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51:1991;4837-4844
39. Lien E.A., Wester K., Lonning P.E., Solheim E., Ueland P.M. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer. 63:1991;641-645
40. Lippman M.E., Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature. 256:1975;592-593
41. Mattson M.P. Calcium as sculptor and destroyer of neural circuitry. Exp. Gerontol. 27:1992;29-49
42. Mattson M.P., Kater S.B. Excitatory and inhibitory neurotransmitters in the generation and degeneration of hippocampal neuroarchitecture. Brain Res. 478:1989;337-348
43. Mattson M.P., Barger S.W., Cheng B., Lieberburg I., Smith-Swintosky V.L., Rydel R.E. Beta-amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16:1993;409-414
44. McDonnell D.P. Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators. Biochem. Soc. Trans. 26:1998;54-60
45. McDonnell D.P. Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen. J. Soc. Gynecol. Invest. 7:2000;S10-S15
46. McMillan P.J., LeMaster A.M., Dorsa D.M. Tamoxifen enhances choline acetyltransferase mRNA expression in rat basal forebrain cholinergic neurons. Brain Res. Mol. Brain Res. 103:2002;140-145
47. Mitlak B.H., Cohen F.J. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm. Res. 48:1997;155-163
48. Mourits M.J., De Vries E.G., Willemse P.H., Ten Hoor K.A., Hollema H., Van der Zee A.G. Tamoxifen treatment and gynecologic side effects: a review. Obstet. Gynecol. 97:2001;855-866
49. Nilsen J. The Role of Estrogen Receptor Subtypes Alpha and Beta in Developmental Neuroprotection and Neurotrophism, (Doctor of Philosophy). 1999;Yale University, New Haven
50. Nilsen J., Brinton R.D. Mitochondrial mechanism of estradiol-mediated neuroprotection. Society for Neuroscience 31st Annual Meeting, San Diego, California:2001
51. Nilsen J., Mor G., Naftolin F. Raloxifene is an Estrogen Agonist, inducing Neurite Outgrowth in PC12 Cells. Society for Gynecologic Investigation. 46th Annual Meeting, Atlanta, GA. 1999
52. Nilsen J., Chen S., Brinton R.D. Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway. Brain Res. 930:2002;216-234
53. O'Neill K., Chen S., Brinton R.D. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp. Neurol. 185:2004;63-80
54. Paganini-Hill A., Clark L.J. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 64:2000;165-176
55. Paganini-Hill A., Henderson V.W. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140:1994;256-261
56. Purdie D.W., Beardsworth S.A. The selective oestrogen receptor modulation: evolution and clinical applications. Br. J. Clin. Pharmacol. 48:1999;785-792
57. Rowlands M.G., Budworth J., Jarman M., Hardcastle I.R., McCague R., Gescher A. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem. Pharmacol. 50:1995;723-726
58. Sandstrom N.J., Williams C.L. Memory retention is modulated by acute estradiol and progesterone replacement. Behav. Neurosci. 115:2001;384-393
59. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:1996;905-912
60. Silva I., Mello L.E., Freymuller E., Haidar M.A., Baracat E.C. Estrogen, progestogen and tamoxifen increase synaptic density of the hippocampus of ovariectomized rats. Neurosci. Lett. 291:2000;183-186
61. Soininen K., Kleimola T., Elomaa I., Salmo M., Rissanen P. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients. J. Int. Med. Res. 14:1986;162-165
62. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., McDonnell D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology. 140:1999;5828-5840
63. Willson T.M., Henke B.R., Momtahen T.M., Charifson P.S., Batchelor K.W., Lubahn D.B., Moore L.B., Oliver B.B., Sauls H.R., Triantafillou J.A., et al. 3-[4-(1, 2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J. Med. Chem. 37:1994;1550-1552
64. Wise P.M., Dubal D.B. Estradiol protects against ischemic brain injury in middle-aged rats. Biol. Reprod. 63:2000;982-985
65. Woolley C.S. Effects of estrogen in the CNS. Curr. Opin. Neurobiol. 9:1999;349-354
66. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., Breitner J.C. Hormone replacement therapy and incidence of Alzheimer disease in older women: the cache county study. JAMA. 288:2002;2123-2129
67. Zhao L., Chen Q., Brinton R.D. Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons. Exp. Biol. Medicine (Maywood). 227:2002;509-519